MaxCyte, Inc. Appointment of Executive VP of Bioprocessing
September 06 2023 - 8:05AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
06 September 2023
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President
of Bioprocessing
ROCKVILLE, MD, September 6, 2023 - MaxCyte, Inc. , (Nasdaq:
MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell-based
therapeutics and to support innovative, cell-based research, today
announced the appointment of Ali Soleymannezhad as Executive Vice
President of Bioprocessing, effective August 21, 2023.
Mr. Soleymannezhad will lead global product development and
marketing strategy for MaxCyte's bioprocessing business. The
bioprocessing business is anchored by the STx and VLx platforms
supporting biotherapeutic research, development and manufacturing
using transient expression to produce complex proteins, vaccines
and biologics at scale.
"With his commercial background, strategic insight and
demonstrated commitment to strong financial performance, Ali will
be a great addition to our executive leadership team," said Doug
Doerfler, President and CEO of MaxCyte. "Ali's diverse experience
will help build upon the initial success we have had with the VLx
in our early access program. With Ali's help, we look forward to
expanded engagement with early access customers and developing new
customer relationships to deliver a large-scale transfection
solution that addresses the current bottlenecks in the cell
bioprocessing market."
Mr. Soleymannezhad brings almost 20 years of technical, sales
and marketing expertise in biomanufacturing, bioprocessing and
bioanalysis to his new role. Most recently, he served as Executive
Vice President for the Separations and Purification business at
Tosoh Bioscience overseeing a team of 140 employees across four
global manufacturing, development, and commercial sites. During his
tenure at Tosoh, Mr. Soleymannezhad was also Vice President of
Global Marketing and Business Development and Director of Sales and
Marketing Americas and served on the board of Semba Biosciences.
Mr. Soleymannezhad received a Master of Business Administration in
finance from Jones Graduate School of Business at Rice University
in Texas after completing his Master and Bachelor of Chemical
Engineering at University of Western Ontario's Faculty of
Engineering in Canada.
"As someone who understands the needs and expectations of life
science customers, one of my goals is to develop and create new and
innovative products and services that will continue to build
MaxCyte's brand," said Mr. Soleymannezhad, EVP of Bioprocessing.
"By executing a compelling marketing strategy that aligns with the
Company's organizational objectives."
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir @maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMZGGLLVFGFZG
(END) Dow Jones Newswires
September 06, 2023 08:05 ET (12:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024